Valion Bio, Inc. VBIO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.59% | 209.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.02% | 154.47% | |||
| Operating Income | -14.02% | -138.73% | |||
| Income Before Tax | -13.37% | -165.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.37% | -165.01% | |||
| Earnings from Discontinued Operations | -300.00% | 104.60% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.53% | -117.69% | |||
| EBIT | -14.02% | -138.73% | |||
| EBITDA | -7.74% | -138.86% | |||
| EPS Basic | 2.60% | -90.27% | |||
| Normalized Basic EPS | 3.28% | -116.84% | |||
| EPS Diluted | 2.60% | -90.27% | |||
| Normalized Diluted EPS | 3.28% | -116.84% | |||
| Average Basic Shares Outstanding | 17.26% | 149.57% | |||
| Average Diluted Shares Outstanding | 17.26% | 149.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||